CGH
ONC

Crossmark Global Holdings’s BeOne Medicines Ltd ONC Stock Holding History

Crossmark Global Holdings’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.06M Buy
10,755
+3,094
+40% +$912K 0.04% 354
2026
Q1 		$2.28M Sell
7,661
-553
-7% -$179K 0.03% 405
2025
Q4 		$2.5M Buy
8,214
+1,973
+32% +$646K 0.04% 384
2025
Q3 		$2.13M Buy
6,241
+1,191
+24% +$362K 0.03% 428
2025
Q2 		$1.22M Buy
5,050
+1,389
+38% +$341K 0.02% 551
2025
Q1 		$996K Sell
3,661
-1,627
-31% -$380K 0.02% 607
2024
Q4 		$977K Buy
5,288
+459
+10% +$93.8K 0.02% 591
2024
Q3 		$1.08M Buy
4,829
+977
+25% +$176K 0.02% 580
2024
Q2 		$550K Sell
3,852
-497
-11% -$76.6K 0.01% 789
2024
Q1 		$680K Buy
4,349
+271
+7% +$43.6K 0.01% 742
2023
Q4 		$736K Sell
4,078
-158
-4% -$28.6K 0.02% 699
2023
Q3 		$748K Buy
4,236
+13
+0.3% +$2.57K 0.02% 659
2023
Q2 		$951K Buy
4,223
+391
+10% +$90K 0.02% 604
2023
Q1 		$825K Buy
3,832
+561
+17% +$135K 0.02% 637
2022
Q4 		$719K Buy
3,271
+99
+3% +$18.2K 0.02% 657
2022
Q3 		$428K Buy
3,172
+670
+27% +$115K 0.01% 835
2022
Q2 		$405K Sell
2,502
-410
-14% -$64K 0.01% 910
2022
Q1 		$549K Buy
2,912
+156
+6% +$33.2K 0.01% 861
2021
Q4 		$747K Buy
2,756
+860
+45% +$290K 0.02% 739
2021
Q3 		$688K Buy
1,896
+210
+12% +$68.7K 0.02% 764
2021
Q2 		$579K Buy
1,686
+240
+17% +$79.5K 0.01% 842
2021
Q1 		$503K Sell
1,446
-300
-17% -$99.3K 0.01% 896
2020
Q4 		$451K Sell
1,746
-120
-6% -$33K 0.01% 889
2020
Q3 		$534K Buy
1,866
+100
+6% +$23.5K 0.02% 741
2020
Q2 		$333K Buy
+1,766
New +$287K 0.01% 955
2020
Q1 		– Sell
-1,946
Closed -$323K – 1379
2019
Q4 		$323K Sell
1,946
-50
-3% -$8.31K 0.01% 1076
2019
Q3 		$244K Buy
1,996
+10
+0.5% +$1.33K 0.01% 1166
2019
Q2 		$246K Sell
1,986
-10
-0.5% -$1.27K 0.01% 1189
2019
Q1 		$263K Sell
1,996
-40
-2% -$5.4K 0.01% 1182
2018
Q4 		$286K Sell
2,036
-480
-19% -$63.7K 0.01% 1105
2018
Q3 		$433K Buy
2,516
+100
+4% +$16.8K 0.01% 1061
2018
Q2 		$371K Sell
2,416
-170
-7% -$30.3K 0.01% 1151
2018
Q1 		$434K Buy
+2,586
New +$350K 0.01% 1012

Other funds holding ONC

WAS
WESPAC Advisors SoCal Pasadena, California $560M AUM 37.11% 1-Year Est. Return
PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
CST
Charles Schwab Trust Henderson, Nevada $1.79B AUM 17.47% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
S
Steadtrust Allen, Texas $198M AUM 99.37% 1-Year Est. Return
AWA
Aaron Wealth Advisors Chicago, Illinois $1.97B AUM 36.91% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

Crossmark Global Holdings's ONC Position: Q2 2026 in Review

Crossmark Global Holdings increased its BeOne Medicines Ltd (ONC) stake by 40% in Q2 2026, buying an estimated $912K and bringing the position to 10,755 shares worth $3.06M. The position accounts for 0.04% of the portfolio, ranked #354.

Crossmark Global Holdings first reported a position in ONC in Q1 2018 and has held it in 33 quarters since. 25 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

  • Crossmark Global Holdings held 10,755 shares of BeOne Medicines Ltd worth $3.06M as of Q2 2026.
  • Crossmark Global Holdings bought 3,094 BeOne Medicines Ltd shares in Q2 2026, an estimated $912K.
  • BeOne Medicines Ltd made up 0.04% of Crossmark Global Holdings's portfolio in Q2 2026, its #354 holding.
  • Crossmark Global Holdings first reported a position in BeOne Medicines Ltd in Q1 2018 and has held it in 33 quarters since.
  • 25 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.